JP2009504654A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009504654A5 JP2009504654A5 JP2008526124A JP2008526124A JP2009504654A5 JP 2009504654 A5 JP2009504654 A5 JP 2009504654A5 JP 2008526124 A JP2008526124 A JP 2008526124A JP 2008526124 A JP2008526124 A JP 2008526124A JP 2009504654 A5 JP2009504654 A5 JP 2009504654A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- yellow fever
- chimeric flavivirus
- fever virus
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70703805P | 2005-08-10 | 2005-08-10 | |
| US60/707,038 | 2005-08-10 | ||
| US71944805P | 2005-09-22 | 2005-09-22 | |
| US60/719,448 | 2005-09-22 | ||
| PCT/US2006/030846 WO2007021672A2 (en) | 2005-08-10 | 2006-08-09 | Vaccination against dengue virus infection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009504654A JP2009504654A (ja) | 2009-02-05 |
| JP2009504654A5 true JP2009504654A5 (enExample) | 2010-08-19 |
| JP5227172B2 JP5227172B2 (ja) | 2013-07-03 |
Family
ID=37758084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008526124A Expired - Fee Related JP5227172B2 (ja) | 2005-08-10 | 2006-08-09 | デングウイルス感染に対するワクチン接種 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080193477A1 (enExample) |
| EP (1) | EP1924280A4 (enExample) |
| JP (1) | JP5227172B2 (enExample) |
| AR (1) | AR055603A1 (enExample) |
| AU (1) | AU2006280144B2 (enExample) |
| BR (1) | BRPI0614265A2 (enExample) |
| CA (1) | CA2618783A1 (enExample) |
| IL (1) | IL189329A (enExample) |
| MY (1) | MY151051A (enExample) |
| NO (1) | NO20081127L (enExample) |
| TW (1) | TW200740458A (enExample) |
| WO (1) | WO2007021672A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2903605A1 (fr) * | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| FR2906724B1 (fr) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
| FR2909286B1 (fr) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
| US8968996B2 (en) | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
| NZ618158A (en) * | 2009-06-01 | 2015-05-29 | Takeda Vaccines Inc | Compositions and methods for administration of vaccines against dengue virus |
| BRPI0904020B8 (pt) | 2009-10-01 | 2021-05-25 | Fundacao Oswaldo Cruz | composição vacinal contra o vírus da dengue, e, kit |
| WO2013151764A1 (en) * | 2012-04-02 | 2013-10-10 | The University Of North Carolina At Chapel Hill | Methods and compositions for dengue virus epitopes |
| WO2014016362A1 (en) | 2012-07-24 | 2014-01-30 | Sanofi Pasteur | Vaccine compositions for prevention against dengue virus infection |
| EP3932422A1 (en) | 2012-07-24 | 2022-01-05 | Sanofi Pasteur | Vaccine compositions for the prevention of dengue virus infection |
| BR112015012515B1 (pt) | 2012-11-30 | 2023-04-11 | Sanofi Pasteur | Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola |
| CA2933472A1 (en) | 2012-12-14 | 2014-06-19 | Takeda Vaccines, Inc. | Compositions, methods of administration and uses for trivalent dengue virus formulations |
| ES2933970T3 (es) | 2013-03-15 | 2023-02-15 | Takeda Vaccines Inc | Composiciones y métodos para construcciones quiméricas de virus del dengue en vacunas |
| SG10201807826XA (en) | 2014-02-11 | 2018-10-30 | Massachusetts Inst Technology | Novel full spectrum anti-dengue antibody |
| GB201704126D0 (en) * | 2017-03-15 | 2017-04-26 | Blom Nihlén Kim Andrea | Vaccine |
| EP3601543A4 (en) * | 2017-03-30 | 2021-01-27 | Merck Sharp & Dohme Corp. | ADDING NUCLEASES DIRECTLY TO CELL CULTURE TO FACILITATE DIGESTION AND RELEASE OF HOST CELL NUCLEIC ACIDS |
| SG11202002933TA (en) | 2017-10-05 | 2020-04-29 | Sanofi Pasteur | Compositions for booster vaccination against dengu |
| CA3111332A1 (en) | 2018-09-05 | 2020-03-12 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| AU2020331884B2 (en) | 2019-08-16 | 2025-01-23 | Takeda Vaccines, Inc. | Methods for preventing dengue and Hepatitis A |
| EP4110381A1 (en) | 2020-02-27 | 2023-01-04 | Takeda Vaccines, Inc. | Method for removing host cell dna from virus preparation |
| WO2023147342A2 (en) | 2022-01-25 | 2023-08-03 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
| EP4479025A1 (en) | 2022-02-15 | 2024-12-25 | Takeda Vaccines, Inc. | Dengue vaccine batch mixing process |
| WO2023215383A1 (en) | 2022-05-04 | 2023-11-09 | Takeda Vaccines, Inc. | Computer-based determination of flavivirus infectivity |
| WO2024108087A1 (en) | 2022-11-18 | 2024-05-23 | Takeda Vaccines, Inc. | A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation |
| WO2024118740A1 (en) | 2022-11-29 | 2024-06-06 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
| WO2025072259A1 (en) | 2023-09-25 | 2025-04-03 | Takeda Vaccines, Inc. | Coadministration of tetravalent dengue vaccine with hpv vaccine |
| WO2025122855A1 (en) | 2023-12-08 | 2025-06-12 | Takeda Vaccines, Inc. | A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184024B1 (en) * | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
| US6676936B1 (en) * | 1988-07-14 | 2004-01-13 | The United States Of America As Represented By The Department Of Health And Human Services. | Chimeric and/or growth-restricted flaviviruses |
| US5605793A (en) * | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6962708B1 (en) * | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
| US7192593B2 (en) * | 1997-05-23 | 2007-03-20 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens |
| US6541011B2 (en) * | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
| AU1813901A (en) * | 1999-12-01 | 2001-06-12 | Oravax, Inc | Chimeric flavivirus vaccines |
| AU2003239932A1 (en) * | 2002-05-31 | 2003-12-19 | Acambis, Inc. | Tetravalent dengue vaccines |
| US6966281B1 (en) * | 2004-05-05 | 2005-11-22 | Hale James R | Internal combustion device and methods of use |
| FR2903605A1 (fr) * | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| FR2906724B1 (fr) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
| FR2909286B1 (fr) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
-
2006
- 2006-08-09 AU AU2006280144A patent/AU2006280144B2/en not_active Ceased
- 2006-08-09 CA CA002618783A patent/CA2618783A1/en not_active Abandoned
- 2006-08-09 JP JP2008526124A patent/JP5227172B2/ja not_active Expired - Fee Related
- 2006-08-09 WO PCT/US2006/030846 patent/WO2007021672A2/en not_active Ceased
- 2006-08-09 EP EP06800943A patent/EP1924280A4/en not_active Ceased
- 2006-08-09 BR BRPI0614265-6A patent/BRPI0614265A2/pt not_active Application Discontinuation
- 2006-08-09 US US12/063,365 patent/US20080193477A1/en not_active Abandoned
- 2006-08-10 AR ARP060103502A patent/AR055603A1/es unknown
- 2006-08-10 MY MYPI20063881 patent/MY151051A/en unknown
- 2006-08-10 TW TW095129386A patent/TW200740458A/zh unknown
-
2008
- 2008-02-06 IL IL189329A patent/IL189329A/en not_active IP Right Cessation
- 2008-03-04 NO NO20081127A patent/NO20081127L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009504654A5 (enExample) | ||
| Martinez-Flores et al. | SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants | |
| Khetarpal et al. | Dengue fever: causes, complications, and vaccine strategies | |
| JP6830118B2 (ja) | ワクチン組成物 | |
| Bråve et al. | Vaccine delivery methods using viral vectors | |
| JP5227172B2 (ja) | デングウイルス感染に対するワクチン接種 | |
| JP2013542224A5 (enExample) | ||
| ES2337893T3 (es) | Vacuna del virus del nilo occidental. | |
| JP2008530245A5 (enExample) | ||
| JP6943908B2 (ja) | 迅速かつ持続的な免疫学的治療法 | |
| ATE526411T1 (de) | Avirulente, immunogene flavivirus-chimäre | |
| Zingaretti et al. | Why is it so difficult to develop a hepatitis C virus preventive vaccine? | |
| CN109843323A (zh) | 用于黄病毒疫苗接种的组合物和方法 | |
| Takei et al. | Oral administration of genetically modified Bifidobacterium displaying HCV-NS3 multi-epitope fusion protein could induce an HCV-NS3-specific systemic immune response in mice | |
| AU2022205163B2 (en) | Hepatitis B immunisation regimen and compositions | |
| JP2010506926A5 (enExample) | ||
| Valiakos et al. | West Nile virus: Basic principles, replication mechanism, immune response and important genetic determinants of virulence | |
| Chen et al. | Advances and perspectives in the development of vaccines against highly pathogenic bunyaviruses | |
| CN116348101A (zh) | 嵌合腺病毒载体 | |
| Kieny et al. | Research and development of new vaccines against infectious diseases | |
| ES2644801T3 (es) | Antígenos de vacuna quimérica contra el virus de la hepatitis c | |
| ES2637629T3 (es) | Inducción de una respuesta inmunitaria frente al virus del dengue usando un enfoque de sensibilización-refuerzo | |
| Sanicas et al. | A review of COVID-19 vaccines in development: 6 months into the pandemic | |
| TW200509964A (en) | VP1 of foot-and-mouth disease virus | |
| US10160979B2 (en) | Pharmaceutical composition for treatment and/or prevention of hepatitis C |